A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

Auckland City Hospital-Cancer & Blood Research ( Site 1051), Auckland

Medical Oncology Centre of Rosebank ( Site 0805), Johannesburg

Nosworthy Oncology ( Site 0807), Johannesburg

Sandton Oncology Medical Group (Pty) Ltd-Research ( Site 0801), Sandton

Port Macquarie - Mid North Coast Cancer Institute-Medical Oncology ( Site 1001), Port Macquarie

Frankston Hospital-Oncology and Haematology ( Site 1007), Frankston

Bowen Hospital ( Site 1050), Wellington

Cancer Care Langenhoven Drive Oncology Centre ( Site 0808), Port Elizabeth

Cape Town Oncology Trials ( Site 0802), Cape Town

CANCERCARE RONDEBOSCH ONCOLOGY-Cancercare Rondebosch Oncology ( Site 0806), Cape Town

Centre Hospitalier Universitaire de Caen Normandie-DERMATOLOGY ( Site 0604), Caen

Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0112), Marietta

Mid Florida Hematology and Oncology Center ( Site 0113), Orange City

Holy Cross Hospital-Clinical Research ( Site 0159), Fort Lauderdale

Russell Medical ( Site 0160), Alexander City

Ege Universitesi Hastanesi ( Site 0902), Izmir

CENTRE LEON BERARD-onco dermatology ( Site 0600), Lyon Cedex08

Highlands Oncology Group-Research Department ( Site 0133), Springdale

Hôpital Bichat - Claude-Bernard ( Site 0605), Paris

Clinique Francois Chenieux ( Site 0603), Limoges

Marin Cancer Care ( Site 0148), Greenbrae

Kadlec Clinic Hematology and Oncology ( Site 0103), Kennewick

Alaska Oncology and Hematology ( Site 0121), Anchorage

ONCOCENTRO APYS-ACEREY ( Site 0400), Viña del Mar

Centro Investigacion Cancer James Lind ( Site 0408), Temuco

Clínica Puerto Montt ( Site 0404), Port Montt

FALP-UIDO ( Site 0401), Santiago

Oncovida ( Site 0403), Santiago

Pontificia Universidad Catolica de Chile-Hemato-Oncology ( Site 0407), Santiago

Bradfordhill-Clinical Area ( Site 0402), Santiago

Instituto de Investigaciones Clínicas Mar del Plata ( Site 0300), Mar del Plata

Fundación Respirar ( Site 0302), Buenos Aires

Instituto San Marcos ( Site 0305), San Juan

HIA Sainte Anne-Pneumology ( Site 0601), Toulon

Bell Land General Hospital ( Site 1101), Sakai

Tokyo Women's Medical University ( Site 1100), Tokyo

Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 0701), Bydgoszcz

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier, Warsaw

Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0702), Koszalin

Zachodniopomorskie Centrum Onkologii ( Site 0703), Szczecin

Steve Biko Academic Hospital-Medical Oncology ( Site 0804), Pretoria

LIFE GROENKLOOF-Mary Potter Cancer Centre ( Site 0800), Pretoria

Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 0903), Adana

Hacettepe Universite Hastaneleri-oncology hospital ( Site 0900), Ankara

Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 0901), Ankara